Trial Profile
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs NYX 2925 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Aptinyx
- 18 Apr 2019 According to an Aptinyx media release, results from this study were presented at the American Pain Society Scientific Meeting in April 2019
- 06 Apr 2019 Trial design presented at the 38th Annual Scientific Meeting of the American Pain Society
- 21 Mar 2019 According to an Aptinyx media release, the company plans to present the data from this study at the American Pain Society Scientific Meeting in April 2019.